59878-28-3

Usage

Uses

Used in Organic Chemistry Research:
4-Chlorocarbonyl-piperazin-1-carboxylic acid tert-butyl ester is used as a research chemical for the development of new compounds and materials in the field of organic chemistry. Its unique structure and properties make it a valuable tool for exploring novel reactions and syntheses.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-chlorocarbonyl-piperazin-1-carboxylic acid tert-butyl ester is used as an intermediate in the synthesis of various drugs and active pharmaceutical ingredients. Its piperazine group is a common structural element in many medications, making 4-CHLOROCARBONYL-PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER a crucial building block in drug development.
Used in Polymer and Resin Synthesis:
4-Chlorocarbonyl-piperazin-1-carboxylic acid tert-butyl ester is utilized as a monomer or a precursor in the production of polymers and resins. Its versatility and reactivity contribute to the creation of materials with specific properties, such as improved strength, flexibility, or chemical resistance.

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 75-44-5 phosgene 
• 147081-80-9 N-(1-piperazinyl)-tert-butoxycarboxamide 
• 503-38-8 trichloromethyl chloroformate 

Downstream Products

• 178972-31-1 4-(4-guanidino-benzylcarbamoyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 384830-32-4 4-[methyl-(4-phenyl-butyl)-carbamoyl]-piperazine-1-carboxylic acid tert-butyl ester 
• 253176-55-5 C₃₄H₄₃N₇O₉ 
• 253176-53-3 C₃₅H₄₅N₇O₉ 
• 253175-38-1 C₄₁H₄₈N₆O₁₀ 
• 479622-29-2 4-(4-phenyl-butylcarbamoyl)-piperazine-1-carbonyl chloride 
• 384830-33-5 4-[methyl-(4-phenyl-butyl)-carbamoyl]-piperazine-1-carbonyl chloride 
• 479622-32-7 (2S,3R)-3-(1-{Benzyloxycarbonylamino-[(E)-benzyloxycarbonylimino]-methyl}-piperidin-3-ylmethyl)-4-oxo-1-[4-(4-phenyl-butylcarbamoyl)-piperazine-1-carbonyl]-azetidine-2-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

SSTR5 ANTAGONISTS

This disclosure is directed, at least in part, to SSTR5 antagonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the SSTR5 antagonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Piperazine ureido derivative, preparation method thereof and application of piperazine ureido derivative in medicine

The invention relates to piperazine ureido derivatives, a preparation method thereof and an application of the piperazine ureido derivatives in medicine. In particular, the invention relates to piperazine ureido derivatives as shown in a general formula (I), a preparation method thereof, pharmaceutical compositions containing the derivatives, and uses thereof as capsid protein inhibitors, especially in prevention and/or treatment of hepatitis B, influenza, herpes, AIDS and other diseases. Wherein the definition of each group in the general formula (I) is the same as that in the specification.

SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS

The present invention relates to substituted alkynylene compounds represented by compound of formula (I) pharmaceutically acceptable salts and stereoisomers thereof. The present invention further provides the methods of preparation of compound of formula (I) and therapeutic uses thereof as anti-cancer agents.

DUAL MAGL AND FAAH INHIBITORS

Provided herein are compounds and pharmaceutical compositions comprising said compounds useful as modulators of MAGL and/or FAAH. The subject compounds and compositions are useful for the treatment of pain and neurological disorders.

SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARAITON AND USE

The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl, wherein two or more of R1, R2, R3, R4, or R5 are other than H; R6 is H, OH, or halogen; and B is a substituted or unsubstituted heterobicycle, wherein when R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is H, R2 is CF3, R3 is H, R4 is CF3, and R5 is H, or R1 is C1, R2 is H, R3 is H, R4 is F, and R5 is H, or R1 is CF3, R2 is H, R3 is F, R4 is H, and R5 is H, or R1 is CF3, R2 is F, R3 is H, R4 is H, and R5 is H, or R1 is C1, R2 is F, R3 is H, R4 is H, and R5 is H, then B is other than or a pharmaceutically acceptable salt thereof.

PHARMACEUTICAL COMPOUNDS

The invention provides kinase inhibitor compounds of the formula (1): or salts, solvates, tautomers or N-oxides thereof; wherein X is O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRC or NRcSO2; m is 0-2; n is 0-1; q is 0-2; A is C1-6 alkylene optionally interrupted by O; R1 is halogen, cyano, nitro, an optionally substituted acyclic C1-6 hydrocarbon group, optionally substituted C3-7 cycloalkyl, optionally substituted phenyl, optionally substituted five membered heteroaryl, NR2R3, Ra-Rb, O-Rb or C(O)NR2R8; R4 is fluorine, chlorine, methyl or cyano; R2 is hydrogen or optionally substituted C1-4 alkyl; R3 is Ra-Rb; or NR2R3 forms a 4 to 7 membered non-aromatic heterocyclic ring; Ra is a bond, C(X2), C(X2)X1, SO, SO2 or SO2 NRc; Rb is hydrogen or an optionally substituted 3 to 7- membered carbocyclic or heterocyclic ring or an optionally substituted C1-12 acyclic hydrocarbon group; Rc is hydrogen or a C1-4 hydrocarbon group; Rd is O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRC, SO2NRc or NRcSO2; X1 is O, S or NRc; X2 is =0, =S or =NRc; but excluding the compound wherein m, n and q are all O, A is CH2 and NR2R3 is a 2-phenylmorpholin-4-yl group

NOVEL DIPHENYLAZETIDINONE SUBSTITUTED BY PIPERAZINE-1-SULFONIC ACID AND HAVING IMPROVED PHARMACOLOGICAL PROPERTIES

The invention therefore relates to the compound of the formula I or a pharmaceutically acceptable salt thereof, its pharmaceutically composition and uses.

Thiazolo-pyrimidine/pyridine urea derivatives

There are presented compounds of the formula or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.

QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF

The present invention relates to a novel quinazoline derivative and a pharmaceutically acceptable salt thereof as a multiplex inhibitor, a method for the preparation thereof, and a pharmaceutical composition and a therapeutic composition comprising same as an active ingredient. The inventive quinazoline derivative as a multiplex inhibitor can selectively and effectively inhibit diseases caused by the overactivity of a tyrosine kinase.

4-AMINOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS PDE4 INHIBITORS

Compounds of formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of phosphodiesterase type IV (PDE4) and are of use in the treatment of inflammatory and/or allergic diseases.